Qure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to ...

Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...

It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news also continued to be in the spotlight.

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

Midway through the new Bob Dylan biopic A Complete Unknown, Dylan has an angry confrontation with his girlfriend, Sylvia ...

A team from the University of North Texas Health Science Center at Fort Worth has conducted the largest characterization of ...

Fintel reports that on December 10, 2024, Raymond James upgraded their outlook for uniQure N.V. (NasdaqGS:QURE) from ...

Good morning! Here are the five things you need to know in local business news to start your busy Wednesday, and Great Scott's development, the World Cup's impact, new JetBlue flights and the great ...

Verition Fund Management LLC lowered its position in uniQure (NASDAQ:QURE – Free Report) by 77.9% during the third quarter, ...

Patients with no detectable cancer after initial therapy for mantle cell lymphoma (MCL) did not experience any survival benefit from undergoing a stem cell transplant compared with maintenance therapy ...

Professor Kjesten Wiig has been appointed Director of the Malaghan Institute of Medical Research at the organisation’s AGM today, as Professor Graham Le Gros continues in a leadership capacity ...

Qure (NASDAQ:QURE – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research note issued to investors on Wednesday. Other research analysts have also ...